Abstract
Arsenic trioxide (ATO) is highly effective in acute promyelocytic leukemia (APL), but despite its multiple mechanism of action, it has no activity in acute myeloid leukemia (AML) that excludes APL (non-APL AML). Ascorbic acid (AA) and ATO induces apoptosis in AML cell lines by depleting intracellular glutathione and generation of reactive oxygen species. In this study, we evaluated the effect of ATO plus AA in patients with non-APL AML. The study enrolled patient aged 18 or older with relapsed or refractory AML (non-APL) after conventional chemotherapy or previously untreated patients 55 years or older who were unfit for standard induction chemotherapy for AML. Intravenous ATO (0.25 mg/kg/day over 1–4 h) was given with intravenous AA (1 g/day over 30 min after ATO) for 5 days a week for 5 weeks (25 doses). Eleven AML patients were enrolled, including six previously untreated elderly patients aged 66–84 years in whom five had antecedent hematological disorder (ADH). Among 10 evaluable patients, one achieved a CR one a CRi and 4 patients had disappearance of blasts from peripheral blood and bone marrow. Five of the six responders were seen in previously untreated elderly patients. ATO related toxicity was mild. The combination of ATO and AA has limited clinical meaningful antileukemia activity in patients with non-APL AML.
Similar content being viewed by others
References
Shigeno K, Naito K, Sahara N et al (2005) Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 82(3):224–229
Soignet SL, Frankel SR, Douer D et al (2011) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860
Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121
Mathews V, George B, Lakshmi KM et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627–2632
Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410
Zhang W, Ohnishi K, Shigeno K et al (1998) The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12:1383–1391
Akao Y, Mizoguchi H, Kojima S et al (1998) Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Hematol 102:1055–1060
Akao Y, Nakagawa Y, Akiyama K (1999) Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455:59–62
Perkins C, Kim CN, Fang G, Bhalla KN (2000) Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95:1014–1022
Cai X, Shen YL, Zhu Q et al (2000) Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14:262–270
Dai J, Weinberg RS, Waxman S et al (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268–277
Jing Y, Dai J, Chalmers-Redman RME et al (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102–2111
Parmar S, Rundhaugen LM, Boehlke L et al (2004) Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 28:909–919
Schiller GJ, Slack J, Hainsworth JD et al (2006) Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24:2456–2464
Vey N, Bosly A, Guerci A et al (2006) Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 24:2465–2471
Lee TC, Wei ML, Chang WJ et al (1989) Elevation of glutathione levels and glutathione S-transferase activity in arsenic-resistant Chinese hamster ovary cells. In Vitro Cell Dev Biol 25:442–448
Ochi T, Kaise T, Oya-Ohta Y (1994) Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells. Experientia 50:115–120
Ochi T, Nakajima F, Sakurai T et al (1996) Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol 70:815–821
Grad JM, Bahlis NJ, Reis I et al (2001) Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98:805–813
Sakagami H, Satoh K (1997) Modulating factors of radical intensity and cytotoxic activity of ascorbate. Anticancer Res 17:3513–3520
Vera JC, Rivas CI, Fischbarg J, Golde DW (1993) Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 364:79–82
Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I et al (2002) Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/ refractory multiple myeloma. Clin Cancer Res 8:3658–3668
Roboz GJ, Ritchie EK, Curcio T et al (2008) Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 113:2504–2511
Burnett AK, Milligan D, Prentice AG et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114–1124
Burnett AK, Hills RK, Hunter A et al (2011) The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25:1122–1127
Acknowledgments
The study was supported by a National Cancer Institute grant R21 CA0998650-02 and by a research grants from Cell Therapeutics Inc. and Cephalon Inc.
Statement to the effect of human studies
The study was approved by the institutional review board of University of Southern California, and a written informed consent was obtained from all patients before study entry.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aldoss, I., Mark, L., Vrona, J. et al. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Ann Hematol 93, 1839–1843 (2014). https://doi.org/10.1007/s00277-014-2124-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-014-2124-y